Waldenström’s Macroglobulinemia

Front Matter....Pages i-ix
Front Matter....Pages 1-1
Waldenström Macroglobulinaemia: Pathological Features and Diagnostic Assessment....Pages 3-19
Waldenström’s Macroglobulinemia Immunophenotype....Pages 21-34
Predispositions and Origins of Waldenstrom Macroglobulinemia: Implications from Genetic Analysis....Pages 35-48
Cytogenetics in Waldenström Macroglobulinemia (WM)....Pages 49-51
Genetic and Signaling Abnormalities in Waldenstrom’s Macroglobulinemia....Pages 53-65
Molecular Pathways in Growth and Survival: Epigenomics....Pages 67-71
The Bone Marrow Microenvironment and Tumor Cells Interactions in Waldenström’s Macroglobulinemia....Pages 73-82
Waldenstrom’s Macroglobulinaemia: Immunosurveillance and the Immune Micro-environment....Pages 83-94
Front Matter....Pages 95-95
Epidemiology of Waldenström Macroglobulinemia....Pages 97-109
Genetic Predisposition to Waldenström Macroglobulinemia....Pages 111-141
Immunoglobulin Type M Monoclonal Gammopathy of Undetermined Significance (IgM-MGUS)....Pages 143-167
Front Matter....Pages 169-169
Hyperviscosity Syndrome, Cold Agglutinin Hemolytic Anemia, and Cryoglobulinemia....Pages 171-183
Neuropathy in Waldenström’s Macroglobulinaemia....Pages 185-194
IgM Amyloidosis....Pages 195-207
The Bing-Neel Syndrome....Pages 209-221
Unusual Manifestations of IgM Monoclonal Gammopathies....Pages 223-236
Front Matter....Pages 237-237
Laboratory Investigations and Findings: Hematological Abnormalities, Biochemical Investigations, Free Light and Heavy Chains....Pages 239-261
Front Matter....Pages 263-263
Response Assessment in Waldenström’s Macroglobulinaemia....Pages 265-275
Front Matter....Pages 277-277
Risk Stratification in Waldenström Macroglobulinemia....Pages 279-293
Front Matter....Pages 295-295
Indications for Treatment of Waldenström’s Macroglobulinemia....Pages 297-313
Front Matter....Pages 295-295
Immunotherapy in Waldenstrom’s Macroglobulinemia....Pages 315-326
Signal Inhibitors in Waldenstrom’s Macroglobulinemia....Pages 327-334
Immunomodulatory Agents and Proteasome Inhibitors in Waldenstrom’s Macroglobulinemia....Pages 335-343
High-Dose Therapy and Haemopoietic Stem Cell Transplantation in Waldenström’s Macroglobulinaemia....Pages 345-355
Long-Term Toxicity of Therapy in Waldenström Macroglobulinemia....Pages 357-365
Treatment Recommendations in Waldenström Macroglobulinemia....Pages 367-370
Back Matter....Pages 371-377